Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZaBeCor Pharmaceutical Co.

Latest From ZaBeCor Pharmaceutical Co.

AstraZeneca moves syk kinase inhibitor into Phase III trials

AstraZeneca has enrolled the first patient in the pivotal programme for the first-in-class Syk kinase inhibitor fostamatinib (previously known as R778). Fostamatinib, which it licensed from Rigel Pharmaceuticals, is being evaluated as a treatment for rheumatoid arthritis (RA) in patients with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX).

Cancer Orthopedics

Novartis enters RNAi area with Quark option deal

Novartis is to pay $10 million for the option to obtain the global licence to develop and commercialise Quark Pharmaceuticals' p53 temporary inhibitor small interfering RNA (siRNA) drug QPI-1002. The drug is currently in Phase II clinical trials for the prevention of acute kidney disease (AKI) in patients undergoing cardiac surgery and for delayed graft function (DGF) in kidney transplant patients.

Metabolic Disorders Cardiovascular
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ZaBeCor Pharmaceutical Co.
  • Senior Management
  • Contact Info
  • ZaBeCor Pharmaceutical Co.
    Philadelphia, PA
    USA
UsernamePublicRestriction

Register